Your Messages Inbox
Your Article Summary
See Latest ArticlesA Comparison of Phase II Study Strategies
Clinical Cancer Research, 10/01/09
Hunsberger S et al. – In this article, the authors compare different phase II study strategies to determine the most efficient drug development path in terms of number of patients and length of time to conclusion of drug efficacy on overall survival.
Related Articles
Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma
American Journal of Clinical Oncology, 10/06/09
Relevance Score: 81%
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
Annals of Oncology, 11/17/09
Relevance Score: 80%
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer
Journal of Clinical Oncology, 10/29/09
Relevance Score: 80%
Effect of timing on the outcomes of 1-phase nonextraction therapy of Class II malocclusion
American Journal of Orthodontics and Dentofacial Orthopedics, 10/29/09
Relevance Score: 80%
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
British Journal of Cancer, 10/19/09
Relevance Score: 80%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Repligen Reports Phase 3 Clinical Trial Results of RG1068 in Pancreatic Imaging
Repligen, 12/10/09
Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology, 12/10/09
Fyi from human genome sciences: gsk initiates second pivotal phase 3 trial for investigational cardiovascular medication darapladib
Human Genome Sciences, 12/10/09
Article Search
Sponsor